<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844986</url>
  </required_header>
  <id_info>
    <org_study_id>D0818C00001</org_study_id>
    <nct_id>NCT01844986</nct_id>
  </id_info>
  <brief_title>Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.</brief_title>
  <acronym>SOLO-1</acronym>
  <official_title>A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myriad Genetic Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line
      Platinum Based Chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib
      Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian
      Cancer following First Line Platinum Based Chemotherapy
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 26, 2013</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Actual">May 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1)</measure>
    <time_frame>Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks thereafter until objective radiological disease progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
    <description>To determine the efficacy by progression free survival (PFS) using investigator assessment according to modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Overall Survival</measure>
    <time_frame>Survival assessed every 4 weeks until treatment discontinues, then every 12 weeks (analysis of data assessed up to a maximum of 54 months). Analysed at the PFS analysis and a further analysis of OS will be performed at approximately 60% maturity.</time_frame>
    <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death</measure>
    <time_frame>CA-125 performed at baseline then every 4 weeks. Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks until objective radiological disease progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
    <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression</measure>
    <time_frame>Following first progression disease then assessed per local practice every 12 weeks until second progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
    <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second progression (PFS2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)</measure>
    <time_frame>Questionnaires will be given to the patient at baseline, at Day 29 and then every 12 weeks for 156 weeks, then every 24 weeks or until the data cut off for the PFS analysis, change in TOI over 24 months reported</time_frame>
    <description>To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to First Subsequent Therapy or Death (TFST)</measure>
    <time_frame>Assessed every 12 weeks following treatment discontinuation. Analysis of data assessed up to a maximum of 54 months. A further analysis of TFST will be performed at approximately 60% OS maturity.</time_frame>
    <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to first subsequent therapy or death (TFST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Second Subsequent Therapy or Death (TSST)</measure>
    <time_frame>Assessed every 12 weeks following treatment discontinuation. Analysis of data assessed up to a maximum of 54 months. A further analysis of TSST will be performed at approximately 60% OS maturity.</time_frame>
    <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second subsequent therapy or death (TSST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Study Treatment Discontinuation or Death (TDT)</measure>
    <time_frame>Time elapsed from randomization to study treatment discontinuation or death. Analysis of data assessed up to a maximum of 54 months. A further analysis of TDT may be performed at approximately 60% OS maturity.</time_frame>
    <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to study treatment discontinuation or death (TDT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS</measure>
    <time_frame>Radiologic scans performed at baseline then every 12 weeks for the first 156 weeks, then every 24 weeks thereafter, assessed until disease progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
    <description>To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and potential future BRCA mutation assays (gene sequencing and large rearrangement analysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Newly Diagnosed</condition>
  <condition>Advanced Ovarian Cancer</condition>
  <condition>FIGO Stage III-IV</condition>
  <condition>BRCA Mutation</condition>
  <condition>Complete Response</condition>
  <condition>Partial Response</condition>
  <condition>First Line Platinum Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Olaparib tablets p.o. 300mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets p.o. twice daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib 300mg tablets</intervention_name>
    <description>Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.</description>
    <arm_group_label>Olaparib tablets p.o. 300mg twice daily</arm_group_label>
    <arm_group_label>Placebo tablets p.o. twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with newly diagnosed, histologically confirmed, high risk advanced
             (FIGO stage III - IV) BRCA mutated high grade serous or high grade endometrioid
             ovarian cancer, primary peritoneal cancer and / or fallopian - tube cancer who have
             completed first line platinum based chemotherapy (intravenous or intraperitoneal).

          -  Stage III patients must have had one attempt at optimal debulking surgery (upfront or
             interval debulking). Stage IV patients must have had either a biopsy and/or upfront or
             interval debulking surgery.

          -  Documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected
             deleterious (known or predicted to be detrimental/lead to loss of function).

          -  Patients who have completed first line platinum (e.g. carboplatin or cisplatin),
             containing therapy (intravenous or intraperitoneal) prior to randomisation:

          -  Patients must have, in the opinion of the investigator, clinical complete response or
             partial response and have no clinical evidence of disease progression on the post
             treatment scan or rising CA-125 level, following completion of this chemotherapy
             course. Patients with stable disease on the post-treatment scan at completion of first
             line platinum-containing therapy are not eligible for the study.

          -  Patients must be randomized within 8 weeks of their last dose of chemotherapy

        Exclusion Criteria:

          -  BRCA1 and/or BRCA2 mutations that are considered to be non detrimental (e.g. &quot;Variants
             of uncertain clinical significance&quot; or &quot;Variant of unknown significance&quot; or &quot;Variant,
             favor polymorphism&quot; or &quot;benign polymorphism&quot; etc).

          -  Patients with early stage disease (FIGO Stage I, IIA, IIB or IIC)

          -  Stable disease or progressive disease on the post-treatment scan or clinical evidence
             of progression at the end of the patient's first line chemotherapy treatment.

          -  Patients where more than one debulking surgery has been performed before randomisation
             to the study. (Patients who, at the time of diagnosis, are deemed to be unresectable
             and undergo only a biopsy or oophorectomy but then go on to receive chemotherapy and
             interval debulking surgery are eligible).

          -  Patients who have previously been diagnosed and treated for earlier stage ovarian,
             fallopian tube or primary peritoneal cancer.

          -  Patients who have previously received chemotherapy for any abdominal or pelvic tumour,
             including treatment for prior diagnosis at an earlier stage for their ovarian,
             fallopian tube or primary peritoneal cancer. (Patients who have received prior
             adjuvant chemotherapy for localised breast cancer may be eligible, provided that it
             was completed more than three years prior to registration, and that the patient
             remains free of recurrent or metastatic disease).

          -  Patients with synchronous primary endometrial cancer unless both of the following
             criteria are met: 1) stage &lt;2 2) less than 60 years old at the time of diagnosis of
             endometrial cancer with stage IA or IB grade 1 or 2, or stage IA grade 3 endometrioid
             adenocarcinoma OR ≥ 60 years old at the time of diagnosis of endometrial cancer with
             Stage IA grade 1 or 2 endometrioid adenocarcinoma. Patients with serous or clear cell
             adenocarcinoma or carcinosarcoma of the endometrium are not eligible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Paul DiSilvestro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women &amp; Infants Hospital, Providence, Rhode Island, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof Kathleen Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma Health Sciences Center, Oklahoma City, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital &amp; Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Women's Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Babak Edraki</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy N. &amp; J.C. Lewis Cancer and Research Pavillion</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital &amp; Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, P.C.</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partners</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Oncology of West MI, PLLC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester, MN</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Valley Cancer Consortium CCOP</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womens Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson at Cooper Cancer Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Care Associates</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Women's Cancer Centers</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center at Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU James Care at Mill Run</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital Cancer Center</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic Women's Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic Gynecological Oncology</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Baycare Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital for Women</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Womens Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Diagnóstico Barretos</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Araujo Jorge</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Novos Tratamentos Itajai</name>
      <address>
        <city>Itajai</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Porto Alagre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base São José do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Referencia da Saude da Mulher</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Câncer de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Norte-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tumor Hospital affiliated to China Medical Science Insti</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Hospital of Jilin university</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Provincial Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital Affiliated to Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChongQing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EC of Cancer Center of SunYet-</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Hospital, Zhejaing University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tumour Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital, Huangzhou</name>
      <address>
        <city>Huangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JINAN, Qi Lu Hosp. of SD Univ.</name>
      <address>
        <city>Ji Nan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetris and Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow Universit</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First affiliated hospital college of XianJiaotong University</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAC François Baclesse</name>
      <address>
        <city>Caen Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>69LYON, C Bérard, Onco</name>
      <address>
        <city>Lyon Cedex 08</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes,</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>75PARIS, H Tenon, Onco</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapir Medical Centre</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin MC</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Centre</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourkasy Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bari- Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Cannizzaro&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Per Cura Tumori - Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto Irccs</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena-Polo Oncologico Ifo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo CC</name>
      <address>
        <city>Akashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hosp</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Kyushu CC</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Med. Univ. Int. Med. C</name>
      <address>
        <city>Hidaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Univ. Med. Dent.</name>
      <address>
        <city>Niigata-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Innowacyjna Medycyna</name>
      <address>
        <city>Grzepnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. Swietej Rodziny SPZOZ</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Udmurtia Republic Clinical Oncology Center</name>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chemotherapy Department, Russian Cancer Research Centre</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Heath Omsk Regional Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg City Oncology Dispensary, Dept. Gynecology</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Oncology Dispensary</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Oncology RAMS</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barcelona,H.Vall d´Hebrón,Oncología</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Córdoba,H.Reina Sofía,Oncología</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.Llobregat,ICO-Duran i Reynals,Oncología</name>
      <address>
        <city>Hospitalet deLlobregat(Barcelo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madrid, MD Anderson, Oncología</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madrid,H.U.La Paz,Oncología</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valencia, IVO, Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valencia,H.C.U.Valencia,Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital, Birmingham, Cancer Trials Team</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arden Cancer Centre</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Research UK Centre</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK and UCL Cancer Trials Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital and Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1817&amp;filename=SOLO1_Clinical%20Study%20Protocol.pdf</url>
    <description>Redacted Clinical Study Protocol</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1817&amp;filename=SOLO1_Statistical%20Analysis%20Plan.pdf</url>
    <description>Redacted Statistical Analysis Plan</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1817&amp;filename=SOLO1_Statistiacal%20Analysis%20Plan..pdf</url>
    <description>Redacted Statistical Analysis Plan</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 30, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>May 9, 2019</results_first_submitted>
  <results_first_submitted_qc>June 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2019</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCA</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>First Line</keyword>
  <keyword>FIGO Stage III</keyword>
  <keyword>FIGO Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT01844986/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT01844986/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient enrolment was from 26 August 2013 to 13 February 2015. Enrolment was at 197 centres in 15 countries. 391 patients were randomized in the Global study. A further 59 were randomized to a separate China cohort (450 randomised in total). The Global study was used for the hypotheses testing of the study.</recruitment_details>
      <pre_assignment_details>It was planned that approximately 344 women with BRCA mutated ovarian cancer patients who are in clinical complete or partial response following first line platinum based chemotherapy were to receive olaparib 300 mg bd or matching placebo in a 2:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olaparib 300mg Tablets</title>
          <description>Taken orally twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo Tablets</title>
          <description>Taken orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olaparib 300mg Tablets</title>
          <description>Taken orally twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo Tablets</title>
          <description>Taken orally twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="260"/>
            <count group_id="B2" value="131"/>
            <count group_id="B3" value="391"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="9.38"/>
                    <measurement group_id="B2" value="53.4" spread="9.79"/>
                    <measurement group_id="B3" value="53.5" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Response to previous platinum chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1)</title>
        <description>To determine the efficacy by progression free survival (PFS) using investigator assessment according to modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</description>
        <time_frame>Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks thereafter until objective radiological disease progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
        <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1)</title>
          <description>To determine the efficacy by progression free survival (PFS) using investigator assessment according to modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</description>
          <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient PFS events to estimate median, lower and upper confidence limit.</measurement>
                    <measurement group_id="O2" value="13.8" lower_limit="11.1" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Overall Survival</title>
        <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of overall survival (OS)</description>
        <time_frame>Survival assessed every 4 weeks until treatment discontinues, then every 12 weeks (analysis of data assessed up to a maximum of 54 months). Analysed at the PFS analysis and a further analysis of OS will be performed at approximately 60% maturity.</time_frame>
        <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Overall Survival</title>
          <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of overall survival (OS)</description>
          <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient OS events to estimate median, lower and upper confidence limit.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Insufficient OS events to estimate median, lower and upper confidence limit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8903</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death</title>
        <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125)</description>
        <time_frame>CA-125 performed at baseline then every 4 weeks. Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks until objective radiological disease progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
        <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death</title>
          <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125)</description>
          <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient events to estimate median, lower and upper confidence limit.</measurement>
                    <measurement group_id="O2" value="12.0" lower_limit="10.8" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression</title>
        <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second progression (PFS2)</description>
        <time_frame>Following first progression disease then assessed per local practice every 12 weeks until second progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
        <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression</title>
          <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second progression (PFS2)</description>
          <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient PFS2 events to estimate median, lower and upper confidence limit.</measurement>
                    <measurement group_id="O2" value="41.9" lower_limit="36.5" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)</title>
        <description>To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL.</description>
        <time_frame>Questionnaires will be given to the patient at baseline, at Day 29 and then every 12 weeks for 156 weeks, then every 24 weeks or until the data cut off for the PFS analysis, change in TOI over 24 months reported</time_frame>
        <population>FAS consisting of all patients who are randomized with a baseline and post baseline TOI scores available</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)</title>
          <description>To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL.</description>
          <population>FAS consisting of all patients who are randomized with a baseline and post baseline TOI scores available</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="-0.717" upper_limit="1.318"/>
                    <measurement group_id="O2" value="3.30" lower_limit="1.839" upper_limit="4.758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed effects for treatment, visit and baseline TOI with the treatment by visit and baseline TOI by visit interaction. Random patient effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.779</ci_lower_limit>
            <ci_upper_limit>-1.216</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to First Subsequent Therapy or Death (TFST)</title>
        <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to first subsequent therapy or death (TFST)</description>
        <time_frame>Assessed every 12 weeks following treatment discontinuation. Analysis of data assessed up to a maximum of 54 months. A further analysis of TFST will be performed at approximately 60% OS maturity.</time_frame>
        <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to First Subsequent Therapy or Death (TFST)</title>
          <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to first subsequent therapy or death (TFST)</description>
          <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="44.3" upper_limit="NA">Insufficient TFST events to estimate the upper confidence limit.</measurement>
                    <measurement group_id="O2" value="15.1" lower_limit="12.7" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Second Subsequent Therapy or Death (TSST)</title>
        <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second subsequent therapy or death (TSST)</description>
        <time_frame>Assessed every 12 weeks following treatment discontinuation. Analysis of data assessed up to a maximum of 54 months. A further analysis of TSST will be performed at approximately 60% OS maturity.</time_frame>
        <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Second Subsequent Therapy or Death (TSST)</title>
          <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second subsequent therapy or death (TSST)</description>
          <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient TSST events to estimate median, lower and upper confidence limit.</measurement>
                    <measurement group_id="O2" value="40.7" lower_limit="32.9" upper_limit="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Study Treatment Discontinuation or Death (TDT)</title>
        <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to study treatment discontinuation or death (TDT).</description>
        <time_frame>Time elapsed from randomization to study treatment discontinuation or death. Analysis of data assessed up to a maximum of 54 months. A further analysis of TDT may be performed at approximately 60% OS maturity.</time_frame>
        <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Study Treatment Discontinuation or Death (TDT)</title>
          <description>To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to study treatment discontinuation or death (TDT).</description>
          <population>Full Analysis Set (FAS) consisting of all patients who are randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="24.0" upper_limit="24.8"/>
                    <measurement group_id="O2" value="13.8" lower_limit="11.2" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS</title>
        <description>To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and potential future BRCA mutation assays (gene sequencing and large rearrangement analysis)</description>
        <time_frame>Radiologic scans performed at baseline then every 12 weeks for the first 156 weeks, then every 24 weeks thereafter, assessed until disease progression. Analysis of data assessed up to a maximum of 54 months.</time_frame>
        <population>FAS consisting of all patients who are randomized and confirmed as Myriad gBRCAm</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib 300mg Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS</title>
          <description>To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and potential future BRCA mutation assays (gene sequencing and large rearrangement analysis)</description>
          <population>FAS consisting of all patients who are randomized and confirmed as Myriad gBRCAm</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient PFS events to estimate median, lower and upper confidence limit.</measurement>
                    <measurement group_id="O2" value="13.8" lower_limit="11.1" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Determined using a log-rank test stratified by response to previous platinum chemotherapy</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model includes a factor for response to previous platinum chemotherapy</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 favours olaparib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events, including Serious Adverse Events, will be collected from time of signature of informed consent, throughout the treatment period and up to and including the 30-day follow-up period after the last dose of study medication. All ongoing and any new AEs/SAEs identified during the 30 calendar days follow up period after last dose of study medication must be followed to resolution.</time_frame>
      <desc>One patient in the placebo arm was randomised and not treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olaparib 300 Tablets</title>
          <description>Taken orally twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Tablets</title>
          <description>Taken orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="17" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Splenic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Medical device site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product by child</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Drug administration error</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cell death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Thyroid cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="156" subjects_affected="90" subjects_at_risk="260"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="84" subjects_affected="40" subjects_at_risk="260"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="21" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="260"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="86" subjects_affected="63" subjects_at_risk="260"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="61" subjects_affected="46" subjects_at_risk="260"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="97" subjects_affected="72" subjects_at_risk="260"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="205" subjects_affected="89" subjects_at_risk="260"/>
                <counts group_id="E2" events="58" subjects_affected="32" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="43" subjects_at_risk="260"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="412" subjects_affected="201" subjects_at_risk="260"/>
                <counts group_id="E2" events="75" subjects_affected="49" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="23" subjects_at_risk="260"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="242" subjects_affected="104" subjects_at_risk="260"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="131" subjects_affected="63" subjects_at_risk="260"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="138" subjects_affected="106" subjects_at_risk="260"/>
                <counts group_id="E2" events="48" subjects_affected="39" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="19" subjects_at_risk="260"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="32" subjects_affected="24" subjects_at_risk="260"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="260"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="38" subjects_affected="27" subjects_at_risk="260"/>
                <counts group_id="E2" events="37" subjects_affected="17" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="260"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="36" subjects_affected="28" subjects_at_risk="260"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="52" subjects_affected="29" subjects_at_risk="260"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="260"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="40" subjects_affected="20" subjects_at_risk="260"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="260"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="68" subjects_affected="51" subjects_at_risk="260"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="260"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="88" subjects_affected="66" subjects_at_risk="260"/>
                <counts group_id="E2" events="47" subjects_affected="35" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="50" subjects_affected="40" subjects_at_risk="260"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="28" subjects_at_risk="260"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="260"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="68" subjects_affected="51" subjects_at_risk="260"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="92" subjects_affected="68" subjects_at_risk="260"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="109" subjects_affected="58" subjects_at_risk="260"/>
                <counts group_id="E2" events="40" subjects_affected="30" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="260"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="260"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="57" subjects_affected="42" subjects_at_risk="260"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="53" subjects_affected="39" subjects_at_risk="260"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="260"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="260"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="260"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The OS data were immature but there was no indication of an OS detriment, with the hazard ratio numerically favouring olaparib. Another analysis of OS will be performed at approximately 60% maturity. Analyses of TFST and TSST will also be performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elizabeth Lowe</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 302 885 1180</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

